<DOC>
	<DOCNO>NCT02232906</DOCNO>
	<brief_summary>Investigation whether switch oral iron intravenous ferric carboxymaltose reduce dose requirement erythropoiesis-stimulating agent ( ESA ) improve Hb level iron status adult patient non-dialysis-dependent CKD stable ESA/oral iron schedule 6 month prior enrolment .</brief_summary>
	<brief_title>Switch From Oral Iron Intravenous Ferric Carboxymaltose Non-dialysis Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>&gt; 18 year age Creatinine clearance ≤40 mL/min Hemoglobin 110120 g/L Serum ferritin &lt; 100 µg/L transferrin saturation &lt; 20 % Monthly treatment ESA oral iron least six month enrolment Other obvious cause acute chronic anemia iron deficiency Expectation require hemodialysis within next six month Short life expectancy ( &lt; 1 year ) Pregnancy Decompensated heart failure History allergic reaction iron preparation and/or anaphylaxis cause Requirement blood transfusion Chronic decompensated mental disorder dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>non-dialysis-dependent</keyword>
	<keyword>ND-CKD</keyword>
	<keyword>Erythropoiesis-stimulating agent</keyword>
	<keyword>Ferric carboxymaltose</keyword>
	<keyword>Iron</keyword>
</DOC>